Liqin Wang

8PUBLICATIONS
51CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical virologyCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 08, 2025
Inducible CRISPR-Cas9 screening platform to interrogate non-proliferative cellular states.

Gabriele Casagrande Raffi, Hendrik J Kuiken, Cor Lieftink

|Jun 02, 2025
Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors.

Min Wang, Yanxing Chen, Lin Tian

|May 13, 2024
A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma.

Alaa Embaby, Sanne C F A Huijberts, Liqin Wang

|Dec 12, 2022
Rational combinations of targeted cancer therapies: background, advances and challenges.

Haojie Jin, Liqin Wang, René Bernards

|Nov 22, 2022
cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis.

Liqin Wang, Haojie Jin, Fleur Jochems

|Sep 06, 2022
Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity.

Ziva Pogacar, Jackie L Johnson, Lenno Krenning

Pageof 2

Frequent Collaborators

6 joint publications

René Bernards

3 joint publications

Rodrigo Leite de Oliveira

2 joint publications

Giulia De Conti

1 joint publications

Lina Lankhorst